Factors influencing growth effects of inhaled corticosteroids in children

A 9-year, 10-month-old boy treated with inhaled corticosteroids (ICSs) for asthma returned to the endocrine clinic for follow-up of linear growth. He began taking Advair Diskus (100/50; GlaxoSmithKline, Research Triangle Park, NC), 1 inhalation twice daily, when he was 4 years old. During treatment with Advair Diskus, he grew steadily along his previous height trajectory at between the 75th and 90th percentiles (Fig 1). Around 6 years of age, treatment was changed to Advair hydrofluoroalkane (HFA; 45/21), 2 inhalations twice daily.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Maintenance of Certification clinical management series Source Type: research